Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06176027RecruitingPhase 1/Phase 2
New drug combo for returning AITL lymphoma
This trial tests a new combination of drugs (azacytidine plus CAOLD) for people with a specific type of T-cell lymphoma called AITL that has come back or not responded to previous treatment. The goal is to see if this treatment can work better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05929729RecruitingPhase 4
Brain study in women with iron deficiency anemia
This is a study that looks at how iron deficiency anemia may affect the brain, and it also checks whether giving iron through an IV is safe and helpful for some participants. You may be in an observation-only group or an iron-treatment group, depending on study testing.
Duarte, CaliforniaAges 16–60 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07679412Recruiting
CMV Retinitis Trial: Your Own Cells vs. Resistant Virus
This trial tests a new treatment made from your own immune cells (called LB-DTK-CMV) for a type of CMV eye infection that is not getting better with standard antiviral drugs. The goal is to see if these cells can safely control the infection and improve your vision.
SeoulAges 19 years+ - NCT07676877RecruitingPhase 1
Low-dose radiation before CAR-T therapy for large B-cell lymphoma
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Columbus, OhioAges 18 years+ - NCT07673367RecruitingPhase 2
Nemtabrutinib with CAR T for relapsed mantle cell lymphoma
This trial tests adding a targeted pill (nemtabrutinib) to standard CAR T-cell therapy for people with mantle cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination works better than CAR T alone.
Nashville, TennesseeAges 18 years+ - NCT07673302Recruiting
Study of drugs to boost fetal hemoglobin in beta thalassemia
This trial tests if certain drugs can safely increase fetal hemoglobin (a type of hemoglobin that helps carry oxygen) in people with beta thalassemia major. It may offer a new way to manage the condition and reduce the need for transfusions.
Rawalpindi, Punjab ProvinceAges Any age - NCT07674498Recruiting
Immune health in older adults with advanced myeloma
This trial studies the immune system of adults 65 and older with multiple myeloma that has come back or not responded to treatment. It looks at how their immune fitness may affect their ability to receive newer therapies like CAR-T cells or bispecific antibodies.
Anderlecht, Brussels CapitalAges 65 years+ - NCT07672210Recruiting
Pregnancy-related aortic dissection in China
This study is looking at cases of aortic dissection that happen during pregnancy or shortly after childbirth in China. It aims to understand how these events occur and how they can best be managed.
Shanghai, Shanghai MunicipalityAges 16–55 - NCT07673614Recruiting
Gentle brain stimulation for nerve pain from chemotherapy
This study tests a gentle brain stimulation technique called transcranial direct current stimulation (tDCS) to see if it can reduce nerve pain, numbness, or tingling caused by chemotherapy. If you've finished cancer treatment but still have these symptoms, this may help improve your quality of life.
Ann Arbor, MichiganAges 18–85 - NCT07672262RecruitingPhase 2
VA maintenance before transplant for intermediate-risk AML
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
Suzhou, JiangsuAges 18 years+ - NCT07677878RecruitingPhase 1
Blinatumomab and low-dose DLI after transplant for B-ALL
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
BeijingAges 18–70 - NCT07677306RecruitingPhase 2
Age-Based Treatment Plan Study for MDS Stem Cell Transplant
This trial tests a conditioning regimen that is adjusted by age for people with low- or intermediate-risk myelodysplastic syndromes (MDS) who are receiving a half-matched (haploidentical) stem cell transplant from a family donor. The goal is to see if an age-stratified approach can improve outcomes.
BeijingAges 18–65 - NCT07672275Recruiting
How blood transfusions affect stress markers in newborns
This study looks at how blood transfusions change stress-related substances in the blood of newborns. It might help doctors understand how transfusions affect babies in the NICU.
Graz, StyriaAges 5 minutes–5 months - NCT06038305Recruiting
Anemia and growth in kids with stomach bug
This study looks at how common anemia (low iron levels) is in children with acute gastroenteritis (stomach bug), and how their growth is affected. It helps doctors understand if more blood tests or growth checks are needed.
AsyutAges 1 month–2 years - NCT05503134RecruitingPhase 1/Phase 2
Donor immune cell treatment for relapsed or stubborn AML
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
Columbus, OhioAges 1–24 - NCT06399107RecruitingPhase 1/Phase 2
Gene therapy trial for sickle cell disease using BAH243
This trial tests a gene therapy that uses a modified virus to deliver a healthy gene to your blood stem cells. It aims to help people with sickle cell disease produce normal red blood cells and reduce painful crises.
Beijing, Beijing MunicipalityAges 2–90 - NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT07664228Recruiting
Predicting stomach pain in children with IgA vasculitis
This study looks at a blood test done when a child is first diagnosed with IgA vasculitis (also called Henoch-Schönlein purpura) to see if it can predict stomach or intestine problems. It involves one extra blood draw at diagnosis and a follow-up visit a few weeks later.
Bursa, BursaAges 2–18 - NCT07665450RecruitingPhase 3
Ramantamig plus daratumumab for untreated multiple myeloma without stem cell transplant
This trial tests a new combination of two drugs, ramantamig and daratumumab, against other standard treatments for people newly diagnosed with multiple myeloma who are not planning to have a stem cell transplant. The goal is to see if this combination works better at controlling the cancer.
NantesAges 18 years+ - NCT07668557RecruitingPhase 1
CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Nanchang, JiangxiAges 18–70 - NCT07671001RecruitingPhase 3
Study of depemokimab for children (6-11) with asthma
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
Mobile, AlabamaAges 6–11 - NCT06073769Recruiting
Safety study of oral azacitidine for AML in Korea
This study is monitoring the safety of the drug oral azacitidine (also called Onureg) when given as maintenance therapy to adults with acute myeloid leukemia (AML). It is designed to track how well patients tolerate the medicine in real-world use in Korea.
SeoulAges 19 years+ - NCT07671378RecruitingPhase 2
Study of zanubrutinib plus sonrotoclax for high-risk CLL/SLL
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Nanjing, JiangsuAges 18–75
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.